Detalles de la búsqueda
1.
Clonal Neoantigen: Emerging "Mechanism-based" Biomarker of Immunotherapy Response.
Cancers (Basel)
; 15(23)2023 Nov 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38067319
2.
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.
Commun Med (Lond)
; 2: 106, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36051466
3.
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.
Proc Natl Acad Sci U S A
; 105(10): 3879-84, 2008 Mar 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-18332425
4.
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia.
PLoS Pathog
; 3(4): e46, 2007 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-17411338
5.
Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients.
HIV Clin Trials
; 9(1): 1-10, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18215977
6.
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
N Engl J Med
; 346(26): 2039-46, 2002 Jun 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-12087139
7.
High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response.
HIV Clin Trials
; 8(4): 193-204, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-17720659
8.
Lack of effect of gastric acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir in HIV-infected patients.
AIDS Patient Care STDS
; 21(4): 247-51, 2007 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-17461719
9.
Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
Clin Drug Investig
; 27(1): 67-74, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-17177581
10.
Substitution with lopinavir/ritonavir improves patient-reported outcomes including quality of life in patients who were intolerant to their antiretroviral therapy.
HIV Clin Trials
; 7(6): 291-308, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-17197377
11.
Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment.
J Clin Pharmacol
; 46(3): 265-74, 2006 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-16490802
12.
Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
Clin Infect Dis
; 41(8): 1186-95, 2005 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16163639
13.
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.
AIDS
; 18(5): 775-9, 2004 Mar 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-15075512
14.
Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.
Antivir Ther
; 7(3): 165-74, 2002 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-12487383
15.
Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection.
HIV Clin Trials
; 5(5): 294-304, 2004.
Artículo
en Inglés
| MEDLINE | ID: mdl-15562370
16.
A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.
J Infect Dis
; 198(2): 234-40, 2008 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18540803
17.
The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect.
J Acquir Immune Defic Syndr
; 44(4): 401-10, 2007 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17224848
18.
A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen.
J Acquir Immune Defic Syndr
; 43(2): 153-60, 2006 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16951643
19.
Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir.
J Infect Dis
; 191(12): 2046-52, 2005 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-15897990
20.
Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
J Virol
; 79(6): 3329-38, 2005 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-15731227